Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 4:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 157 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Central Venous Cannula Insertion Clear all
Completed Phase 4 Interventional Results available

Prophylactic Antimicrobial Catheter Lock

NCT00571259
View directory record Official record
Conditions
Bacteremia
Interventions
Heparin 1000U/mL, 4% Sodium Citrate with Gentamicin 320 mcg/mL
Drug
Lead sponsor
Satellite Healthcare
Other
Eligibility
Not listed
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Mountain View, California
Source: ClinicalTrials.gov public record
Updated Sep 22, 2021 · Synced Oct 6, 2026, 4:55 PM EDT
Withdrawn Phase 2 Interventional

Evaluate Efficacy of Devimistat in Combination With mFFX in 2nd Line Patients With Metastatic Pancreatic Cancer

NCT06518538
View directory record Official record
Conditions
Pancreatic Cancer Stage IV
Interventions
CPI-613, modified Folfirinox
Drug
Lead sponsor
Cornerstone Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Aug 15, 2024 · Synced Oct 6, 2026, 4:55 PM EDT
Completed Phase 2Phase 3 Interventional

A Safety and Efficacy Study Evaluating CTX001 in Participants With Transfusion-Dependent β-Thalassemia

NCT03655678
View directory record Official record
Conditions
Beta-Thalassemia, Thalassemia, Genetic Diseases, Inborn, Hematologic Diseases, Hemoglobinopathies
Interventions
CTX001
Biological
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years to 35 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
6
States / cities
Palo Alto, California • Chicago, Illinois • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 6, 2026, 4:55 PM EDT
Completed Phase 2 Interventional Results available

Surgery Plus Chemotherapy (Doxorubicin, Vincristine and Etoposide), Mitotane, and Tariquidar to Treat Adrenocortical Cancer

NCT00071058
View directory record Official record
Conditions
Adrenal Cortex Neoplasms
Interventions
XR9576 (Tariquidar)
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 18, 2012 · Synced Oct 6, 2026, 4:55 PM EDT
Terminated Phase 2 Interventional Results available

Phase II Study of Doxorubicin and Avastin® in Sarcoma.

NCT00755261
View directory record Official record
Conditions
Sarcoma, Soft Tissue Sarcoma
Interventions
Avastin, Doxorubicin
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 8, 2015 · Synced Oct 6, 2026, 4:55 PM EDT
Completed Phase 2 Interventional Results available

Busulfan and Fludarabine in Patients With AML and MDS

NCT00502905
View directory record Official record
Conditions
Leukemia
Interventions
Busulfan, Fludarabine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 66 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 28, 2012 · Synced Oct 6, 2026, 4:55 PM EDT
Recruiting Not applicable Interventional

Manipulation and Dry Needling in Patients With Cervicogenic Headache and WAD II

NCT06502951
View directory record Official record
Conditions
Cervicogenic Headache, Whiplash Injuries
Interventions
Dry Needling,Thrust Manipulation, Exercise,Non-thrust Mobilization
Other
Lead sponsor
Alabama Physical Therapy & Acupuncture
Other
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Montgomery, Alabama
Source: ClinicalTrials.gov public record
Updated May 11, 2025 · Synced Oct 6, 2026, 4:55 PM EDT
Completed Not applicable Interventional Results available

Pediatric Catheter-related Thrombosis Imaging Study

NCT01137578
View directory record Official record
Conditions
Thrombosis
Interventions
Ultrasound, Magnetic Resonance Imaging with Contrast, Magnetic Resonance Imaging without Contrast
Procedure · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
Up to 18 Years
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
10
States / cities
Little Rock, Arkansas • Aurora, Colorado • Kansas City, Missouri + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2014 · Synced Oct 6, 2026, 4:55 PM EDT
Recruiting Not applicable Interventional

A Study of Cardiac Magnetic Resonance Imaging (CMR) for Evaluating Catheter-Associated Right Atrial Clot in People With Cancer

NCT07549477
View directory record Official record
Conditions
Adult Cancer Patients, Right Atrial Clot
Interventions
Cardiac MRI
Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 6, 2026, 4:55 PM EDT
Completed Not applicable Interventional

Spinal Manipulation and Dry Needling Versus Conventional Physical Therapy in Patients With Sacroiliac Dysfunction

NCT02373644
View directory record Official record
Conditions
Sacroiliac Joint Dysfunction
Interventions
HVLA Thrust Manipulation and DN, Conventional Physical Therapy
Other
Lead sponsor
Alabama Physical Therapy & Acupuncture
Other
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Montgomery, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 19, 2020 · Synced Oct 6, 2026, 4:55 PM EDT
Completed No phase listed Observational

Thenar Tissue Oxygen Concentration (StO2): A Non-invasive Surrogate for Central Venous Oxygen Saturation (ScvO2)

NCT02476630
View directory record Official record
Conditions
Oxygen Concentration Levels
Interventions
StO2 measurement, Blood Gases
Device · Other
Lead sponsor
University of Florida
Other
Eligibility
1 Month to 21 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 22, 2018 · Synced Oct 6, 2026, 4:55 PM EDT
Completed Phase 3 Interventional Results available

Calcineurin Inhibitor-Free Interventions BMT CTN 1301 for Prevention of Graft-versus-Host Disease (BMT CTN 1301)

NCT02345850
View directory record Official record
Conditions
Acute Leukemia, Myelodysplasia
Interventions
Unmanipulated Bone Marrow Graft with Tacrolimus/Methotrexate, Mobilized CD34-selected Peripheral Blood Stem Cell graft, Unmanipulated Bone Marrow Graft with Cyclophosphamide, Cyclophosphamide, Tacrolimus, Methotrexate
Procedure · Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
1 Year to 65 Years
Enrollment
346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
28
States / cities
Duarte, California • Stanford, California • Gainesville, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2023 · Synced Oct 6, 2026, 4:55 PM EDT
Terminated Phase 2 Interventional Results available

Donor Stem Cell Transplant in Treating Patients With Myeloid Cancer or Other Disease

NCT00392782
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes
Interventions
anti-thymocyte globulin, fludarabine phosphate, thiotepa, peripheral blood stem cell transplantation, total-body irradiation
Biological · Drug · Procedure + 1 more
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 60 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
9
States / cities
Tampa, Florida • Atlanta, Georgia • Indianapolis, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Oct 6, 2026, 4:55 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Simulation-based Training for Surgery Residents in Aseptic Techniques

NCT00787345
View directory record Official record
Conditions
Nosocomial Infections
Interventions
simulation based training
Other
Lead sponsor
St. Luke's-Roosevelt Hospital Center
Other
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 22, 2010 · Synced Oct 6, 2026, 4:55 PM EDT
Completed Phase 2 Interventional Results available

Transplantation for Patients With Sickle Cell Disease From Mismatched Family Donors of Bone Marrow

NCT02757885
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Bone Marrow Transplant (BMT), Hydroxyurea, Thiotepa, Fludarabine monophosphate, Cyclophosphamide, Rabbit Anti-thymocyte Globulin, Total Body Irradiation
Procedure · Drug · Other + 1 more
Lead sponsor
Emory University
Other
Eligibility
15 Years to 40 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 12, 2023 · Synced Oct 6, 2026, 4:55 PM EDT
Completed Phase 2 Interventional Results available

Vyxeos(CPX-351) in Adults w R/R Acute Lymphoblastic Leukemia

NCT03575325
View directory record Official record
Conditions
Lymphoid Leukemia, Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia, Relapsed Acute Lymphoblastic Leukemia
Interventions
CPX-351
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 12, 2024 · Synced Oct 6, 2026, 4:55 PM EDT
Completed Phase 2 Interventional

Trial of a Novel Fibrinolytic (Alfimeprase) to Clear Thrombosed Vascular Access Devices

NCT00073515
View directory record Official record
Conditions
Catheters, Indwelling
Interventions
Alfimeprase
Drug
Lead sponsor
ARCA Biopharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 3, 2010 · Synced Oct 6, 2026, 4:55 PM EDT
Active, not recruiting Phase 3 Interventional

UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy

NCT00572169
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Velcade, Thalidomide, Dexamethasone, Adriamycin, Cisplatin, Cyclophosphamide, Etoposide
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2027
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 6, 2026, 4:55 PM EDT
Terminated Not applicable Interventional

Can Ultrasound be Used to Verify CVC Position and to Exclude Pneumothorax?

NCT00388375
View directory record Official record
Conditions
Catheterization, Central Venous
Interventions
Ultrasound
Procedure
Lead sponsor
Christiana Care Health Services
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Oct 20, 2014 · Synced Oct 6, 2026, 4:55 PM EDT
Withdrawn Phase 2 Interventional

Safety and Effectiveness Study of CPI-613 and/or Gemcitabine to Treat Metastatic Pancreatic Cancer

NCT01830322
View directory record Official record
Conditions
Metastatic Pancreatic Adenocarcinoma
Interventions
CPI-613, Gemcitabine, Any non-gemcitabine chemotherapies or best supportive care
Drug
Lead sponsor
Cornerstone Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
2
States / cities
The Bronx, New York • Temple, Texas
Source: ClinicalTrials.gov public record
Updated Aug 14, 2013 · Synced Oct 6, 2026, 4:55 PM EDT
Recruiting Phase 1 Interventional

Study of Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone for Relapsed B-cell ALL

NCT06863259
View directory record Official record
Conditions
B-cell Acute Lymphoblastic Leukemia
Interventions
Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
1 Year to 39 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Oct 6, 2026, 4:55 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Acupuncture for Stroke Recovery

NCT02926378
View directory record Official record
Conditions
Systematic Acupuncture
Interventions
Acupuncture Treatments
Procedure
Lead sponsor
NYU Langone Health
Other
Eligibility
20 Years to 60 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 17, 2020 · Synced Oct 6, 2026, 4:55 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Medical Residents Performance: Effect of Simulation-Based Training

NCT00612131
View directory record Official record
Conditions
Healthy
Interventions
Not listed
Lead sponsor
St. Luke's-Roosevelt Hospital Center
Other
Eligibility
Not listed
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 17, 2012 · Synced Oct 6, 2026, 4:55 PM EDT
Terminated Phase 2 Interventional Results available

Catheter-Related Early Thromboprophylaxis With Enoxaparin (CRETE) Trial

NCT03003390
View directory record Official record
Conditions
Deep Venous Thrombosis
Interventions
Enoxaparin
Drug
Lead sponsor
Yale University
Other
Eligibility
Up to 17 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
6
States / cities
New Haven, Connecticut • St Louis, Missouri • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2020 · Synced Oct 6, 2026, 4:55 PM EDT